Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.

Breast cancer research and treatment - 1 Jul 2012

Grob Tobias J, Heilenkötter Uwe, Geist Stefan, Paluchowski Peter, Wilke Christian, Jaenicke Fritz, Quaas Alexander, Wilczak Waldemar, Choschzick Matthias, Sauter Guido, Lebeau Annette

Abstract excerpt

Women with triple-negative breast cancer (TNBC) do not benefit from endocrine therapy or trastuzumab. Chemotherapy is the only systemic therapy currently available. To reduce the elevated risk of disease progression in these patients, better treatment options are needed, which are less toxic and more targeted to this patient population. We performed a comprehensive analysis of potential targetable genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Ductal, Breast

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogenes

Share to Receptor, ErbB-2

Share to Receptor Protein-Tyrosine Kinases

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Tissue Array Analysis

Source

Identifiers

PMID: 22610646
DOI: 10.1007/s10549-012-2092-7

Genes

EGFR
ALK
BRAF
KRAS
EML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.PMID 22610646Read ↗

Genetic Markers in Triple-Negative Breast Cancer.Semantic proximity Read ↗

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Semantic proximity Read ↗

Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.Semantic proximity Read ↗

Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer.Semantic proximity Read ↗

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.Semantic proximity Read ↗

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.Semantic proximity Read ↗

Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.Semantic proximity Read ↗

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.Semantic proximity Read ↗

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other MalignanciesSemantic proximity Read ↗

Prognostic markers in triple-negative breast cancer.Semantic proximity Read ↗

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Semantic proximity Read ↗

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.